See our latest statement here
6 / 61 articles displayed
News
As a leading business in the healthcare industry, we understand the gravity of the situation and the challenge ahead of us. The management of Quotient Sciences has been closely monitoring the ongoing COVID-19 situation and taking steps to limit any potential impact it could have on our trial subjects, our staff, our customers, our community, and our business.
News
The Faculty of Engineering and School of Pharmacy, at the University of Nottingham, are delighted to announce the receipt of an MRC Confidence in Concepts grant. Working in collaboration with Quotient Sciences, Added Scientific and AstraZeneca, the grant will translate towards clinical applications some of the advances made at Nottingham in the 3D printing of pharmaceutical dosage forms.
News
Quotient Sciences, today announced plans to present on the latest Tufts CSDD White Paper assessing the timeline reductions and multi-million dollar cost savings of Translational Pharmaceutics® at Biotech Showcase 2020™, to be held January 13-15, during the most important week in healthcare at the Hilton San Francisco Union Square.
Awards
Quotient Sciences has won the Deal of the Year award at the 2019 Medilink East Midlands Business Awards. The Deal of the Year award recognises entrepreneurship of an individual or team in executing a truly transformational and high-value deal for both the company and the East Midlands Life Sciences sector
News
Tufts Center for the Study of Drug Development (CSDD) today published a white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug, compared to traditional multi-vendor development paradigms.
News
Quotient Sciences, the innovative drug development and manufacturing organization, today announces the appointment of Claes Glassell as non‐executive chairman of its board of directors. A highly accomplished leader in the pharmaceutical industry with over 35 years’ experience, Glassell has held numerous leadership positions, including at the board level, to help companies through high phases of growth.
Ask us a question